Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe/simvastatin switch versus rosuvastatin or statin dose doubling in diabetic patients with cardiovascular disease
2008-007689-52Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ezetimibe, simvastatin, rosuvastatin and atorvastatin in hypercholesterolemia (3 arms), sponsored by Merck & Co. Primary endpoint: Percent change from baseline in LDL-C at endpoint. Started Mar 2009; status: completed.
02
Drugs
ezetimibesimvastatinrosuvastatinatorvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2008-007689-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007689-52.